Free Trial

The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Qsemble Capital Management LP

Cooper Companies logo with Medical background

Qsemble Capital Management LP lessened its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 85.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,666 shares of the medical device company's stock after selling 40,049 shares during the quarter. Qsemble Capital Management LP's holdings in Cooper Companies were worth $736,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Cooper Companies by 3.0% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 7,820,590 shares of the medical device company's stock valued at $682,738,000 after buying an additional 231,155 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Cooper Companies by 23.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company's stock valued at $435,856,000 after acquiring an additional 737,726 shares during the last quarter. Impax Asset Management Group plc raised its holdings in Cooper Companies by 31.0% in the 2nd quarter. Impax Asset Management Group plc now owns 2,359,798 shares of the medical device company's stock valued at $205,511,000 after acquiring an additional 558,886 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Cooper Companies by 8.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,818,345 shares of the medical device company's stock worth $200,636,000 after purchasing an additional 134,875 shares during the period. Finally, Swedbank AB boosted its holdings in shares of Cooper Companies by 16.6% during the second quarter. Swedbank AB now owns 1,600,420 shares of the medical device company's stock worth $139,717,000 after purchasing an additional 228,000 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Morgan Stanley upped their target price on Cooper Companies from $95.00 to $104.00 and gave the company an "equal weight" rating in a research note on Tuesday, September 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a research note on Wednesday. Stifel Nicolaus reissued a "buy" rating and issued a $115.00 target price (up from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. StockNews.com downgraded shares of Cooper Companies from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Wells Fargo & Company increased their price target on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an "overweight" rating in a research note on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $117.00.

View Our Latest Analysis on COO

Insider Transactions at Cooper Companies

In related news, CFO Brian G. Andrews sold 24,788 shares of the firm's stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now directly owns 6,614 shares of the company's stock, valued at approximately $700,422.60. This trade represents a 78.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Agostino Ricupati sold 1,601 shares of the business's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the transaction, the chief accounting officer now owns 4,818 shares in the company, valued at $520,488.54. This represents a 24.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 256,373 shares of company stock valued at $27,637,427 over the last quarter. Company insiders own 2.00% of the company's stock.

Cooper Companies Trading Down 0.0 %

Shares of Cooper Companies stock traded down $0.03 during trading hours on Wednesday, hitting $102.61. The company's stock had a trading volume of 156,484 shares, compared to its average volume of 1,128,683. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $20.44 billion, a PE ratio of 57.18, a P/E/G ratio of 2.21 and a beta of 0.99. The business has a fifty day moving average of $105.74 and a 200 day moving average of $98.39. The Cooper Companies, Inc. has a 1-year low of $82.21 and a 1-year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm's revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.84 earnings per share. As a group, equities analysts forecast that The Cooper Companies, Inc. will post 3.65 EPS for the current year.

About Cooper Companies

(Free Report)

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

Further Reading

Institutional Ownership by Quarter for Cooper Companies (NASDAQ:COO)

Should you invest $1,000 in Cooper Companies right now?

Before you consider Cooper Companies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cooper Companies wasn't on the list.

While Cooper Companies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs

MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs

Bitcoin soared 60% since the election, reigniting interest in the crypto market. Crypto-related stocks like MicroStrategy are now seeing a big boost too.

Recent Videos

MicroStrategy Stock: Riding Bitcoin’s Wave to New Highs
How Abacus Life is Transforming Life Insurance into Assets | MarketBeat CEO Series
NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines